open access
Renal amyloidosis secondary to rheumatoid arthritis effectively treated with tocilizumab
Affiliations- Katedra Reumatologii i Rehabilitacji, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
open access
Abstract
Kidney amyloidosis is one of the most serious potential complication of chronic inflammatory disorders, including rheumatoid arthritis. Interleukin-6 blockade is frequently effective in rheumatic disease, however, there are only few published data on its use in AA amyloidosis. Here, we report a case of patient with rheumatoid arthritis complicated by nephrotic syndrome due to secondary type A amyloidosis successfully treated with tocilizumab.
Forum Reumatol. 2018, tom 4, nr 3: 184–186
Abstract
Kidney amyloidosis is one of the most serious potential complication of chronic inflammatory disorders, including rheumatoid arthritis. Interleukin-6 blockade is frequently effective in rheumatic disease, however, there are only few published data on its use in AA amyloidosis. Here, we report a case of patient with rheumatoid arthritis complicated by nephrotic syndrome due to secondary type A amyloidosis successfully treated with tocilizumab.
Forum Reumatol. 2018, tom 4, nr 3: 184–186
Keywords
rheumatoid arthritis; kidney amyloidosis; tocilizumab
About this articleTitle
Renal amyloidosis secondary to rheumatoid arthritis effectively treated with tocilizumab
Journal
Issue
Article type
Case report
Pages
184-186
Published online
2018-10-26
Page views
765
Article views/downloads
733
DOI
Bibliographic record
Forum Reumatol 2018;4(3):184-186.
Keywords
rheumatoid arthritis
kidney amyloidosis
tocilizumab
Authors
Dorota Sikorska
Włodzimierz Samborski
References (14)- Mohamed N, Nasr SH. Renal Amyloidosis. Surg Pathol Clin. 2014; 7(3): 409–425.
- Wang YH, Zhang YG. Amyloid and immune homeostasis. Immunobiology. 2017.
- Cohen A, Jones L. Amyloidosis. Current Opinion in Rheumatology. 1991; 3(1): 125–138.
- Horak P, Smrzova A, Krejci K, et al. Renal manifestations of rheumatic diseases. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157(2): 98–104.
- Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly. 2012; 142: w13580.
- Król E, Perkowska-Ptasińska A, Oko A. Kidney involvement in rheumatoid arthritis – diagnostic and management recommendations. Nefrol Dial Pol. 2016; 20: 127–133.
- Mittal T, Rathi M. Rheumatological diseases and kidneys: a nephrologist's perspective. Int J Rheum Dis. 2014; 17(8): 834–844.
- Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014; 8: 349–364.
- Smolen JS, Landewe R, Bijlsma J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases. 2017; 76(6): 960–977.
- Courties A, Grateau G, Philippe P, et al. Club Rhumatismes Inflammation and the REGATE Registry. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid. 2015; 22(2): 84–92.
- Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006; 54(9): 2997–3000.
- Vinicki JP, De Rosa G, Laborde HA. Renal amyloidosis secondary to rheumatoid arthritis: remission of proteinuria and renal function improvement with tocilizumab. J Clin Rheumatol. 2013; 19(4): 211–213.
- Miyagawa I, Nakayamada S, Saito K, et al. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol. 2014; 24(3): 405–409.
- Uda H, Saiki O. Tocilizumab postpones the start of hemodialysis compared to conventional oral treatment in amyloid A amyloidosis patients with advanced renal insufficiency by suppressing serum SAA levels. Amyloid. 2017; 24(1): 62–63.
